Carerx Corporation · TSX:CRRX
Carerx — Q1 2021 Earnings Presentation
15 slides from Carerx's earnings presentation, May 13, 2021
Slide 1: Q1 2021 Earnings Call
Slide 2: Forward Looking Statements
Forward Looking Statements Certain of the statements contained in this presentation are "forward looking information within the meaning of applicable Canadian securities legislation. Forward looking information includes, but is not limited to, business strategy, plans and other expectations, beliefs
Slide 3: David Murphy, President & Chief Executive Officer
David Murphy President & Chief Executive Officer
Slide 4: A Very Strong Start to 2021
A Very Strong Start to 2021 3 acquisitions including our most significant to date: Will further expand bed count by ~85% Strong year-over-year growth in revenue and Adjusted EBITDA
Slide 5: Q1 2021 Financial Highlights
QI 2021 Financial Highlights From Continuing Operations (+/- compared to QI 2020) + Average beds serviced of 48,703 +55% vs QI/20 (millions) Qi 2021 * Growth driven primarily by Revenue $44.9 +47% Remedy’s acquisition Q2/20 Adjusted EBITDA $4.1 +100% * Adjusted EBITDA includes full realization of an
Slide 6: Medical Pharmacies Acquisition
Medical Pharmacies Acquisition April 19, 2021: Definitive Agreement to Acquire LTC Division of Medical Pharmacies Will add ~36,000 beds, serviced through 18 centres in Ontario & Western Canada Further expands Canada’s largest national platform Expected to contribute run-rate annualized revenue of ~$
Slide 7: Rexall Acquisition
Rexall Acquisition * Consideration: * April 23, 2021: Signed definitive agreement * $3.5 M cash (on hand) to acquire a portion of Rexall LTC Pharmacy Business * Closing targeted for June * Rexall has made the strategic decision » Further opportunity for CareRx to to exit the business of providing ph
Slide 8: Other Highlights
Other Highlights Qi/21 Announced & completed (April 1) acquisition of SmartMeds Added ~2,400 residents serviced in Ontario Expected to contribute run-rate annualized revenue of ~$13.0 M & Adj. EBITDA of ~$1.5 M, prior to integration synergies Substantially completed onboarding of 1,100 beds from mul
Slide 9: Andrew Mok, Chief Financial Officer
Andrew Mok Chief Financial Officer
Slide 10: Q1 2020 vs Q1 2021 Financial Results
• • 50 45 • 40 35 30 • 25 20 15 • 10 5 0 Q1 2020 Q1 2021
Slide 11: Q1 2021 Financial Results | Adjusted EBITDA
QI 2021 Financial Results | Adjusted EBITDA Bb Q1 2020 (millions) $4.1 Q1 2021 * 100% year-over-year growth * Includes >$3.0 M in annualized cost saving synergies achieved from the consolidation of certain fulfillment centres and other operating cost savings that were fully realized * QI/21 Adjusted
Slide 12: Data prior to pending equity financing and debt refinancing
ALL DATA BELOW IS PRIOR TO PENDING EQUITY FINANCING & DEBT REFINANCING ANNOUNCED APRIL 19, 2021 • • • • •
Slide 13: David Murphy, President & Chief Executive Officer
David Murphy President & Chief Executive Officer
Slide 14: Well positioned to continue to execute on growth strategy
: wa: CareRx Remain well positioned to Today continue to execute on + Medical g rowth strategy Pharmacies & Rexall Strengthened leadership position, expanded national & enhanced capabilities Total Continuing to aggressively pursue organic growth Market Opportunity via Canadian seniors home pharmacy
Slide 15: Questions
J *.. Questions Visit our website at www.carerx.ca | Follow @CareRx on Twitter $$ CareRx